Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and Zymeworks (ZYME)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perrigo Company (PRGO) and Zymeworks (ZYME) with bullish sentiments.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Perrigo Company (PRGO)
In a report released today, Susan Anderson from Canaccord Genuity maintained a Buy rating on Perrigo Company, with a price target of $17.00. The company’s shares closed last Monday at $11.61.
According to TipRanks.com, Anderson is a 5-star analyst with an average return of
Currently, the analyst consensus on Perrigo Company is a Moderate Buy with an average price target of $17.00.
See the top stocks recommended by analysts >>
Zymeworks (ZYME)
Truist Financial analyst Asthika Goonewardene initiated coverage with a Buy rating on Zymeworks today and set a price target of $28.00. The company’s shares closed last Monday at $23.93.
According to TipRanks.com, Goonewardene is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $37.38 average price target, implying a 56.3% upside from current levels. In a report issued on June 1, Wells Fargo also maintained a Buy rating on the stock with a $34.00 price target.
Read More on PRGO:
